This Could Be One of the Best Ways to Treat Mental Health Issues for Millions

Over the last 20 years, “The number of psychopharmacological drugs research programs in larger drug firms has shrunk by 70% in the past decade,” reported The Guardian. “In general the larger companies have walked away from psychiatry. There are a few companies who have maintained efforts in the area but 70% tells you it’s been a pretty remarkable departure. Many withdrew from neuroscience entirely.” Of course, that needs to change, which is why companies like Silo Wellness (CSE:SILO), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Tryp Therapeutics Inc. (CSE:TRYP), Field Trip Health Ltd. (CSE:FTRP)(OTC:FTRPF), and Compass Pathways Inc. (NASDAQ:CMPS) are all fighting to advance psychedelics as a potential treatment.

Psilocybin for example may be helpful with anxiety, PTSD, opioid addictions, obsessive-compulsive disorder (OCD), and alcoholism. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR, for example. New York Univ. found “Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreases in cancer-related demoralization and hopelessness, improved spiritual well-being.”

Look at Silo Wellness (CSE:SILO) for example

Silo Wellness a leading wellness company in the psychedelics and functional mushroom marketplaces, today announced a series of psilocybin-assisted wellness retreats beginning in May. Based in Montego Bay, these retreats are one component of Silo Wellness’ existing psilocybin operations in Jamaica, where the Company currently conducts mushroom and truffle cultivation and testing of the Company’s patent-pending nasal spray.

“We are prioritizing the expansion of our wellness retreat offerings to meet rising consumer demand for these transformative psychedelic experiences,” said Chief Executive Officer Douglas K. Gordon. “Setting and mindset have a profound influence on an individual’s experience, and our Jamaican retreats offer idyllic, natural backdrops for engaging in psilocybin-assisted exploration, introspection and self-actualization.”

The new line-up of psilocybin-assisted retreats range from four to six days and are expected to take place in Jamaica between May and August of 2021. Each retreat presents a tailored offering for distinct audiences and interests:

Renew, Restore & Revitalize - Women’s Psilocybin-Assisted Retreat
May 29, 2021 - June 2, 2021
This five-day/four-night psilocybin-assisted women’s retreat taps into divine feminine energy to guide visitors towards a more fulfilling and satisfying life.

Ultimate Pride & Love - Psychedelic Retreat
June 9, 2021 - June 13, 2021
This five-day/four-night retreat is designed as a safe space for members of the LGBTQIA+ community to embark upon their psilocybin-assisted journey together.

Body & Mind Recharge - Psilocybin-Enhanced Fitness Retreat
June 16, 2021 - June 21, 2021
Guests will build strength and resilience in body and mind on this six-day/five-night retreat, combining intense workout regimes and transformational psilocybin-assisted ceremonies.

Mushroom Grower's Workshop
July 17, 2021 - July 20, 2021
At this four-day/three-night retreat, would-be cultivators will learn the secrets of growing magic mushrooms from some of the first legal professionals in the industry.

Couples Connection - Psilocybin-Enhanced Retreat
July 21 - July 31, 2021
This five-day/four-night retreat is designed for couples seeking a psychedelic journey to build a deeper mutual connection and more satisfying romantic relationship.

Silo Wellness is the leading psilocybin cultivator and facilitator of psychedelic retreats in Jamaica, a jurisdiction where the cultivation, extraction, and consumption of psilocybin mushrooms is not illegal.

For more information about Silo Wellness psychedelic retreats, or to register, visit Each registration is subject to screening and approval by facilitators, and no medical treatment or psychotherapy is offered or available at the retreat. Mushrooms and these retreats do not cure or mitigate any physical or mental disease, symptoms, disorders, or abnormalities.

Other related developments from around the markets include:

Cybin Inc. announced plans to advance the pre-clinical work for its orally dissolving tablet formulation of CYB003 and its inhaled formulation of CYB004, two of the Company’s deuterated tryptamine development candidates. These studies are part of the required U.S. Food and Drug Administration enabling trials for investigational new drug applications. Upon successful completion, the results of the IND-enabling studies will be included in the submissions to the FDA, as well as to other regulatory bodies, such as Health Canada and European Medical Association. The candidates would then advance into Phase 1 human clinical trials for specified psychiatric conditions. Labcorp Drug Development will serve as the pre-clinical research organization for Cybin.

Tryp Therapeutics Inc., a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced it has initiated quoting activity on the OTCQB® Venture Market and is eligible for settlement and transfer of its common shares in the United States with The Depository Trust Company. The Company's common shares are currently quoted on the OTCQB under the symbol "TRYPF" and will continue to trade on the Canadian Securities Exchange under the symbol "TRYP". DTC is a subsidiary of the Depository Trust & Clearing Corporation and manages the electronic clearing and settlement of publicly traded companies. DTC eligibility incorporates an electronic method of clearing securities that accelerates the receipt of stock and cash, reduces costs, and allows the stock to be traded over a much wider selection of brokerage firms by meeting their clearing and settlement requirements.

Field Trip Health Ltd., a leader in the development and delivery of psychedelic therapies, reported its third fiscal quarter results for the three and nine months ended December 31, 2020. Joseph del Moral, Field Trip’s CEO, said, “We are making rapid progress maximizing value for shareholders by building out Field Trip’s complementary business lines that focus on both the development and the delivery of psychedelic therapies. Our deeply integrated platform combines drug and product developments, psychedelic-enhanced therapy and technology-enabled virtual care solutions. All the components work in concert with each other to increase our understanding of the therapeutic value of psychedelics and to deliver them to patients that need them most. With our early-mover advantage, a strong cash position, and a strong and growing reputation as thought leaders in the industry, we are well-positioned to propel our growth in the emerging market of psychedelic therapy.” 

Compass Pathways Inc., a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has been granted two new patents by the US Patent and Trademark Office (USPTO). These patents cover oral formulations of COMPASS’s synthetic psilocybin in the treatment of major depressive disorder (MDD), which includes treatment-resistant depression (TRD). US Patent No 10,954,259 was granted on 23 March 2021, with claims to COMPASS’s high-purity crystalline psilocybin (including the form used in its synthetic formulation, COMP360), pharmaceutical formulations containing crystalline psilocybin and methods of treating MDD with the crystalline psilocybin.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Silo Wellness has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of Silo Wellness. Please click here for full disclaimer.

Contact Information:
[email protected]